
SMARCB1 Antibody rSMARCB1/4588 / Integrase interactor 1 Monoclonal Antibody [clone rSMARCB1/4588] (V9581)

Catalog No.	Formulation	Size
V9581-100UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide	100 ug
V9581-20UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide	20 ug
V9581SAF-100UG	1 mg/ml in 1X PBS; BSA free, sodium azide free	100 ug


Recombinant | MOUSE MONOCLONAL

Bulk quote request

Availability	1-3 business days
Species Reactivity	Human
Format	Purified
Host	Mouse
Clonality	Recombinant Mouse Monoclonal
Isotype	Mouse IgG1, kappa
Clone Name	rSMARCB1/4588
Purity	Protein A/G affinity
UniProt	Q12824
Localization	Nucleus
Applications	Immunohistochemistry (FFPE): 1-2ug/ml
Limitations	This SMARCB1 Antibody rSMARCB1/4588 / Integrase interactor 1 Monoclonal Antibody is available for research use only.



SMARCB1 Antibody rSMARCB1/4588 Immunohistochemistry Analysis. IHC staining of FFPE human Ewing sarcoma with SMARCB1 antibody (clone rSMARCB1/4588). HIER: boil tissue sections in pH 9 10mM Tris with 1mM EDTA for 20 min and allow to cool before testing.



IHC staining of FFPE human epithelioid sarcoma tissue with SMARCB1 antibody (clone rSMARCB1/4588). Note loss of nuclear expression in tumor cells and retained positivity in normal cells. HIER: boil tissue sections in pH 9 10mM Tris with 1mM EDTA for 20 min and allow to cool before testing.

Description

SMARCB1 Antibody rSMARCB1/4588 detects SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 protein. The SMARCB1 gene, which encodes a functionally uncharacterized protein component of the hSWI/SNF chromatin remodeling complex, is often mutated or deleted in malignant rhabdoid tumor (MRT). Two isoforms of INI-1, that differ by the variable inclusion of amino acids, potentially are produced by differential RNA splicing. The morphology of MRTs can present challenges in differential diagnosis. The overall survival of MRTs relative to its potential mimics (medulloblastoma, supratentorial primitive neuroectodermal tumors (sPNETs) is quite low, and thus differentiation from these other tumors is desirable. Lack of nuclear labeling by anti-INI-1 is characteristic of MRT. The majority of medulloblastomas and sPNETs are labeled by anti-INI-1. MRTs also originate from the kidney and soft tissues.

For an antibody with protein microarray specificity validation, see our INI1 Antibody SMARCB1/3984.

Application Notes

Optimal dilution of the SMARCB1 Antibody rSMARCB1/4588 / Integrase interactor 1 Monoclonal Antibody should be determined by the researcher.

Immunogen

A portion of amino acids 257-359 was used as the immunogen for the SMARCB1 Antibody rSMARCB1/4588.

Storage

Aliquot the SMARCB1 Antibody rSMARCB1/4588 and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Copyright © NSJ Bioreagents. All rights reserved.